Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Bonelli, RM; Niederwieser, G; Tribl, GG; Költringer, P.
High-dose olanzapine in Huntington's disease.
Int Clin Psychopharmacol. 2002; 17(2):91-93
Doi: 10.1097%2F00004850-200203000-00009
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Bonelli Raphael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The few reports available on olanzapine in Huntington's disease (HD) are insufficiently documented and/or insufficiently dosed. We describe a 30-year-old woman with genetically confirmed HD who presented with severe chorea. She was not able to eat or dress without help and did not respond to haloperidol; the motor scale of the Unified HD Rating Scale (UHDRS-I) revealed 65 of a possible 124 points. After admission, we treated the patient with a high dose of olanzapine (30 mg daily). The chorea almost ceased in the next 2 days, she was able to eat and walk without assistance (UHDRS-I of 21 points), and fine motor tasks improved, as well as gait and eye movements. This effect lasted for 5 months. We conclude that high-dose olanzapine appears to be useful in grave choreatic attacks.
- Find related publications in this database (using NLM MeSH Indexing)
- Activities of Daily Living -
- Adult -
- Antipsychotic Agents - administration and dosage
- Benzodiazepines - administration and dosage
- Eye Movements - administration and dosage
- Female - administration and dosage
- Gait - administration and dosage
- Humans - administration and dosage
- Huntington Disease - drug therapy
- Neurologic Examination - drug therapy
- Pirenzepine - administration and dosage
- Psychomotor Performance - administration and dosage
- Find related publications in this database (Keywords)
- Huntington's disease
- neuroleptics
- olanzapine
- severe chorea